EVALUATION OF THE EFFECTIVENESS OF 3-MONTH TRIPTORELIN IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY AT THE VIET NAM NATIONAL CHILDREN’S HOSPITAL (2018–2023)
Main Article Content
Abstract
Objective: To evaluate the effectiveness of 3-month triptorelin in the treatment of central precocious puberty (CPP) at the Viet Nam National Children’s Hospital from 2018 to 2023.
Methods: A prospective cohort study was conducted on 45 girls diagnosed with CPP who were initially treated with intramuscular triptorelin 11.25 mg every 3 months.
Results: The mean height gain was 3 ± 1.11 cm after 6 months, corresponding to a growth velocity of approximately 6–6.2 cm/year, approaching the physiological range. Serum levels of LH, FSH, and estradiol decreased in both groups; however, statistically significant reductions were observed only in the group treated with 3-month triptorelin from the beginning. Uterine size decreased and returned to prepubertal values in both groups, with statistically significant changes observed in group 1. The bone age/chronological age ratio significantly decreased in group 1, indicating better suppression of bone maturation. No adverse effects were observed during the 6-month follow-up period.
Conclusion: Triptorelin, particularly the 3-month depot formulation used from the outset, demonstrated significant effectiveness in the treatment of central precocious puberty after 6 months. The therapy effectively suppressed the hypothalamic–pituitary–gonadal axis, slowed bone maturation, improved morphological parameters, and normalized growth velocity, with no short-term adverse effects observed.
Keywords
Central precocious puberty, triptorelin
Article Details
References
2. A.-S. Parent, G. Teilmann, A. Juul, N. E. Skakkebaek, J. Toppari, and J.-P. Bourguignon, "The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration," (in eng), Endocrine reviews, vol. 24, no. 5, pp. 668-693, 2023.
3. G. Teilmann, C. B. Pedersen, N. E. Skakkebaek, and T. K. Jensen, "Increased risk of precocious puberty in internationally adopted children in Denmark," (in eng), Pediatrics, vol. 118, no. 2, pp. e391-e399, 2016.
4. J. S. Fuqua, "Treatment and outcomes of precocious puberty: an update," (in eng), The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 6, pp. 2198-2207, 2013.
5. K. O. Klein, K. M. Barnes, J. V. Jones, P. P. Feuillan, and G. B. Cutler Jr, "Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience," (in eng), The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 10, pp. 4711-4716, 2021.
6. J.-C. Carel, E. A. Eugster, A. Rogol, L. Ghizzoni, M. R. Palmert, and m. o. t. E.-L. G. A. C. C. Group, "Consensus statement on the use of gonadotropin-releasing hormone analogs in children," (in eng), Pediatrics, vol. 123, no. 4, pp. e752-e762, 2019.
7. E. A. Eugster, "Treatment of central precocious puberty," (in eng), Journal of the Endocrine Society, vol. 3, no. 5, pp. 965-972, 2019.
8. A. C. Latronico, V. N. Brito, and J.-C. Carel, "Causes, diagnosis, and treatment of central precocious puberty," (in eng), The lancet Diabetes & endocrinology, vol. 4, no. 3, pp. 265-274, 2016.